LeMaitre Q2 2025 Financial Results

Core Insights - LeMaitre Vascular, Inc. reported strong Q2 2025 results, with significant sales growth driven by catheters and grafts, and announced a quarterly dividend of $0.20 per share [1][3][6] Financial Performance - Q2 2025 sales reached $64.2 million, a 15% increase compared to Q2 2024, with organic growth also at 15% [3][10] - Gross margin improved to 70.0%, up from 68.9% in Q2 2024, attributed to higher average selling prices and manufacturing efficiencies [3][10] - Operating income for Q2 was $16.1 million, reflecting a 12% increase year-over-year [3][10] - Earnings per share (EPS) rose 16% to $0.60 per fully diluted share [3][10] Sales Growth Drivers - Sales growth was primarily driven by a 27% increase in catheter sales and a 19% increase in graft sales [3] - Regional sales performance included a 23% increase in EMEA, and 12% growth in both Americas and APAC [3] Guidance and Outlook - The company raised its guidance for Q3 2025, projecting sales between $61.2 million and $63.2 million, and for the full year 2025, sales are expected to be between $248 million and $254 million [4] - Gross margin and operating margin are expected to remain stable at 69.7% and 24% respectively for both Q3 and full year guidance [4] Dividend and Share Repurchase - The Board of Directors approved a quarterly dividend of $0.20 per share, payable on September 4, 2025 [6] - A share repurchase program was authorized for up to $75 million, set to conclude on February 17, 2026, unless extended [7] Cash Position - The company reported a sequential increase in cash of $16.9 million, bringing total cash to $319.5 million [10]